Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04624451 · ClinicalTrials.gov registry record
Evaluation of Intravenous Dalbavancin for Peritonitis
A clinical trial, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- 2
- Enrollment target
NCT04624451: Clinical Trial study, sponsored by University of Colorado, Denver.
NCT04624451 is a clinical trial that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04624451 was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.
Primary Outcome
resolution of signs and symptoms (e.g. abdominal pain), bacterial eradication, reduction in clinical markers (e.g. peritoneal fluid findings, CRP, etc), and return of peritoneal dialysis functionality
Interventions
- DRUG Dalbavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2024-01-31 |
Why NCT04624451 stopped before completion
NCT04624451 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dalbavancin is the first listed.
NCT04624451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04624451 about?
NCT04624451 is a clinical study titled "Evaluation of Intravenous Dalbavancin for Peritonitis". This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.
What is the current status of trial NCT04624451?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2020-06-01. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT04624451?
The interventions under investigation include: Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT04624451?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI